Topical treatment of malignant and premalignant skin lesions by very low concentrations of a standard mixture (BEC) of solasodine glycosides

Cancer Lett. 1991 Sep;59(3):183-92. doi: 10.1016/0304-3835(91)90140-d.


A cream formulation containing high concentrations (10%) of a standard mixture of solasodine glycosides (BEC) has been shown to be effective in the treatment of malignant and benign human skin tumours. We now report that a preparation (Curaderm) which contains very low concentrations of BEC (0.005%) is effective in the treatment of keratoses, basal cell carcinomas (BCCs) and squamous cell carcinomas (SCCs) of the skin of humans. In an open study, clinical and histological observations indicated that all lesions (56 keratoses, 39 BCCs and 29 SCCs) treated with Curaderm had regressed. A placebo formulation had no effect on a smaller number of treated lesions. Curaderm had no adverse effect on the liver, kidneys or haematopoietic system.

Publication types

  • Clinical Trial
  • Controlled Clinical Trial

MeSH terms

  • Administration, Topical
  • Carcinoma, Basal Cell / drug therapy*
  • Carcinoma, Squamous Cell / drug therapy*
  • Glycosides
  • Humans
  • Keratosis / drug therapy*
  • Pharmaceutical Vehicles
  • Phytosterols / administration & dosage*
  • Precancerous Conditions / drug therapy*
  • Skin Neoplasms / drug therapy*
  • Solanaceous Alkaloids / administration & dosage*


  • Glycosides
  • Pharmaceutical Vehicles
  • Phytosterols
  • Solanaceous Alkaloids
  • beta-solamarine
  • alpha-solamargine